More importantly, either deletion of the GSK-3β gene through CRISPR-Cas9 technology or GSK-3β knockdown by shRNA leads to lymphoma cell growth arrest at the G2/M phase of the cell cycle [170]. The gene discussed is GSK3B; the disease is lymphoma.